Pioneering Therapeutic Frontiers

Pioneering Therapeutic Frontiers

TRANSFORMING TREATMENTS FOR CANCER AND INFLAMMATORY DISEASES WITH OUR REVOLUTIONARY PLATON™ PLATFORM

MORE

Endless possibilities

Valerio Therapeutics is a clinical-stage biotechnology company leading the way in the development of innovative DNA decoy therapeutics.
Focusing exclusively on intracellular DNA-binding targets, we design and develop first-in-class treatments for oncology and inflammatory diseases precision therapeutics.

Strategic Partnerships

Our collaborative partnerships set us above other therapeutic companies, leveraging our unique treatments to diversify the delivery of life-changing benefits.

Strong Expertise & Clear Strategy

Clinical Expertise
Licensing Agreements
World-class Advisors

Unique Science

Creating Innovative Compounds
Distinctive Mechanisms
Addressing New & Multiple Pathways

DNA Decoy Therapeutics

First-in-class product in DDR currently in clinical trials
Only decoy agonist in development

Latest News

  • Valerio Therapeutics: 16.8 million euros in cash, visibility until the 2nd quarter of 2024
    Valerio Therapeutics: 16.8 million euros in cash, visibility until the 2nd quarter of 2024

    September 29, 2023

  • Valerio Therapeutics: , largest increase in the SRD market at mid-session
    Valerio Therapeutics: , largest increase in the SRD market at mid-session

    August 30, 2023

  • Le Journal des Biotechs | Interview of Shefali Agarwal, President and CEO of Onxeo (in French)
    Le Journal des Biotechs | Interview of Shefali Agarwal, President and CEO of Onxeo (in French)

    April 20, 2023